• Keep this leaflet. You may need to read it again.
• If you have any further questions, ask your doctor or pharmacist.
• This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
• If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

1. What Mirtazapine tablet is and what it is used for
2. What you need to know before you take Mirtazapine tablets
3. How to take Mirtazapine tablets
4. Possible side effects
5. How to store Mirtazapine tablets
6. Contents of the pack and other information

• if you are allergic (hypersensitive) to mirtazapine or any of the other ingredients of this medicine (listed in section 6). If so, you must talk to your doctor as soon as you can before taking Mirtazapine tablets.
• if you are taking or have recently taken (within the last two weeks) medicines called monoamine oxidase inhibitors (MAO-Is).
• If you have ever developed a severe skin rash or skin peeling, blistering and/or mouth sores after taking Mirtazapine tablets or other medicinal product(s).

Talk to your doctor or pharmacist before taking Mirtazapine tablets:

• If you are taking buprenorphine-containing medicinal products. The use of these medicines together with Mirtazapine can lead to serotonin syndrome, a potentially life-threatening condition (see “Other medicines and Mirtazapine tablets.”).

Mirtazapine should normally not be used for children and adolescents under 18 years because efficacy was not demonstrated. Also, you should know that patients under 18 have an increased risk of side-effects such as suicide attempt, suicidal thoughts and hostility (predominantly aggression, oppositional behaviour and anger) when they take this class of medicines. Despite this, your doctor may prescribe Mirtazapine tablets for patients under 18 because he/she decides that this is in their best interests. If your doctor has prescribed Mirtazapine tablets for a patient under 18 and you want to discuss this, please go back to your doctor. You should inform your doctor if any of the symptoms listed above develop or worsen when patients under 18 are taking Mirtazapine tablets. Also, the long-term safety effects concerning growth, maturation and cognitive and behavioural development of Mirtazapine in this age group have not yet been demonstrated. In addition, significant weight gain has been observed in this age category more often when treated with Mirtazapine compared with adults.

If you are depressed you can sometimes have thoughts of harming or killing yourself. These may be increased when first starting antidepressants, since these medicines all take time to work, usually about two weeks but sometimes longer.

You may be more likely to think like this:

• if you have previously had thoughts about killing or harming yourself.
• if you are a young adult. Information from clinical trials has shown an increased risk of suicidal behaviour in adults aged less than 25 years with psychiatric conditions who were treated with an antidepressant.

• If you have thoughts of harming or killing yourself at any time, contact your doctor or go to a hospital straight away.

You may find it helpful to tell a relative or close friend that you are depressed, and ask them to read this leaflet. You might ask them to tell you if they think your depression is getting worse, or if they are worried about changes in your behaviour.

Also take special care with Mirtazapine

• if you have, or have ever had one of the following conditions.
  • Tell your doctor about these conditions before taking Mirtazapine, if not done previously.
    • seizures (epilepsy). If you develop seizures or your seizures become more frequent, stop taking Mirtazapine and contact your doctor immediately;
    • liver disease, including jaundice. If jaundice occurs, stop taking Mirtazapine and contact your doctor immediately;
    • kidney disease;
    • heart disease, or low blood pressure;
    • schizophrenia. If psychotic symptoms, such as paranoid thoughts become more frequent or severe, contact your doctor straightaway;
    • manic depression (alternating periods of feeling elated/overactivity and depressed mood). If you start feeling elated or over-excited, stop taking Mirtazapine and contact your doctor immediately;
    • diabetes (you may need to adjust your dose of insulin or other antidiabetic medicines);
    • eye disease, such as increased pressure in the eye (glaucoma);
    • difficulty in passing water (urinating), which might be caused by an enlarged prostate.
    • certain kinds of heart conditions that may change your heart rhythm, a recent heart attack, heart failure, or take certain medicines that may affect the heart’s rhythm.
• if you develop signs of infection such as inexplicable high fever, sore throat and mouth ulcers.
  • Stop taking Mirtazapine and consult your doctor immediately for a blood test.
    In rare cases these symptoms can be signs of disturbances in blood cell production in the bone marrow. While rare, these symptoms most commonly appear after 4-6 weeks of treatment.
• if you are an elderly person. You could be more sensitive to the side-effects of antidepressants.
• Serious skin reactions including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported with the use of Mirtazapine tablets. Stop using and seek medical attention immediately if you notice any of the symptoms described in section 4 in relation to these serious skin reactions.

If you have ever developed any severe skin reactions, treatment with Mirtazapine tablets should not be restarted.

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.

Do not take Mirtazapine in combination with:

• monoamine oxidase inhibitors (MAO inhibitors). Also, do not take Mirtazapine during the two weeks after you have stopped taking MAO inhibitors. If you stop taking Mirtazapine, do not take MAO inhibitors during the next two weeks either.

Examples of MAO inhibitors are moclobemide, tranylcypromine (both are antidepressants) and selegiline (used for Parkinson’s disease).

Take care when taking Mirtazapine in combination with:

• antidepressants such as SSRIs, venlafaxine and L-tryptophan, or triptans (used to treat migraine), tramadol (a pain-killer), linezolid (an antibiotic), lithium (used to treat some psychiatric conditions), methylene blue (used to treat high levels of methemoglobin in the blood) and St. John’s Wort – Hypericum perforatum preparations (a herbal remedy for depression). In very rare cases Mirtazapine alone or the combination of Mirtazapine with these medicines, can lead to a so-called serotonin syndrome. Some of the symptoms of this syndrome are: inexplicable fever, sweating, increased heart rate, diarrhoea, (uncontrollable) muscle contractions, shivering, overactive reflexes, restlessness, mood changes, and unconsciousness. If you get a combination of these symptoms, talk to your doctor immediately.
• the antidepressant nefazodone. It can increase the amount of Mirtazapine in your blood. Inform your doctor if you are using this medicine. It might be needed to lower the dose of Mirtazapine, or when use of nefazodone is stopped, to increase the dose of Mirtazapine again.
• medicines for anxiety or insomnia such as benzodiazepines;
  medicines for schizophrenia such as olanzapine;
  medicines for allergies such as cetirizine;
  medicines for severe pain such as morphine.
  In combination with these medicines Mirtazapine can increase the drowsiness caused by these medicines.
• medicines for infections; medicines for bacterial infections (such as erythromycin); medicines for fungal infections (such as ketoconazole) and medicines for HIV/AIDS (such as HIV-protease inhibitors) and drugs for stomach ulcers (such as cimetidine). In combination with Mirtazapine these medicines can increase the amount of Mirtazapine in your blood. Inform your doctor if you are using these medicines. It might be needed to lower the dose of Mirtazapine, or when these medicines are stopped, to increase the dose of Mirtazapine again.
• medicines for epilepsy such as carbamazepine and phenytoin;
  medicines for tuberculosis such as rifampicin.
  In combination with Mirtazapine these medicines can reduce the amount of Mirtazapine in your blood. Inform your doctor if you are using these medicines. It might be needed to increase the dose of Mirtazapine, or when these medicines are stopped to lower the dose of Mirtazapine again.
• medicines to prevent blood clotting such as warfarin.
  Mirtazapine can increase the effects of warfarin on the blood. Inform your doctor if you are using this medicine. In case of combination it is advised that a doctor monitors your blood carefully.
• medicines that may affect the heart’s rhythm such as certain antibiotics and some anti psychotics.
• Buprenorphine-containing medical products. These medicines may interact with Mirtazapine and you may experience symptoms such as involuntary, rhythmic contractions of muscles, including the muscles that control movement of the eye, agitation, hallucinations, coma, excessive sweating, tremor, exaggeration of reflexes, increased muscle tension, body temperature above 38°C. Contact your doctor when experiencing such symptoms.

You may get drowsy if you drink alcohol while you are taking Mirtazapine.

You are advised not to drink any alcohol.

You can take Mirtazapine tablets with or without food.

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

Limited experience with Mirtazapine administration to pregnant women does not indicate an increased risk. However, caution should be exercised when used during pregnancy.

If you use Mirtazapine tablets until, or shortly before birth, your baby should be supervised for possible adverse effects.

Make sure your midwife and/or doctor knows you are on Mirtazapine tablets. When taken during pregnancy, similar drugs (SSRIs) may increase the risk of a serious condition in babies, called persistent pulmonary hypertension of the newborn (PPHN), making the baby breathe faster and appear bluish. These symptoms usually begin during the first 24 hours after the baby is born. If this happens to your baby you should contact your midwife and/or doctor immediately.

Mirtazapine tablets can affect your concentration or alertness. Make sure these abilities are not affected before you drive or operate machinery. If your doctor has prescribed Mirtazapine tablets for a patient under 18 years make sure the concentration and alertness is not affected before participation in traffic (e.g. on bicycle).

If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.

The recommended starting dose is 15 or 30 mg every day. Your doctor may advise you to increase your dose after a few days to the amount that is best for you (between 15 and 45 mg per day). The dose is usually the same for all ages. However, if you are an elderly person or if you have renal or liver disease, your doctor may adapt the dose.

• Take Mirtazapine tablets at the same time each day.

It is best to take Mirtazapine tablets as a single dose before you go to bed. However your doctor may suggest to split your dose of Mirtazapine tablets – once in the morning and once at night-time before you go to bed. The higher dose should be taken before you go to bed.

Take your tablets orally. Swallow your prescribed dose of Mirtazapine tablets without chewing, with some water or juice.

Usually Mirtazapine tablets will start working after 1 to 2 weeks and after 2 to 4 weeks you may start to feel better.

It is important that, during the first few weeks of the treatment, you talk with your doctor about the effects of Mirtazapine tablets:

• 2 to 4 weeks after you have started taking Mirtazapine tablets, talk to your doctor about how this medicine has affected you.

If you still don’t feel better, your doctor may prescribe a higher dose. In that case, talk to your doctor again after another 2 to 4 weeks. Usually you will need to take Mirtazapine tablets until your symptoms of depression have disappeared for 4 to 6 months.

• If you or someone else have taken too much Mirtazapine tablets, call a doctor straight away.

The most likely signs of an overdose of Mirtazapine tablets (without other medicines or alcohol) are drowsiness, disorientation and increased heart rate. The symptoms of a possible overdose may include changes to your heart rhythm (fast, irregular heartbeat) and/or fainting which could be symptoms of a life-threatening condition known as Torsade de Pointes.

If you are supposed to take your dose once a day

• Do not take a double dose to make up for a forgotten dose. Take your next dose at the normal time.
  If you are supposed to take your dose twice a day
• if you have forgotten to take your morning dose, simply take it together with your evening dose.
• if you have forgotten to take your evening dose, do not take it with the next morning dose; just skip it and continue with your normal morning and evening doses.
• if you have forgotten to take both doses, do not attempt to make up for the missed doses. Skip both doses and continue the next day with your normal morning and evening doses.

• Only stop taking Mirtazapine tablets in consultation with your doctor.

If you stop too early, your depression might come back. Once you are feeling better, talk to your doctor. Your doctor will decide when treatment can be stopped.

Do not suddenly stop taking Mirtazapine tablets, even when your depression has lifted. If you suddenly stop taking Mirtazapine tablets you may feel sick, dizzy, agitated or anxious, and have headaches. These symptoms can be avoided by stopping gradually. Your doctor will tell you how to decrease the dose gradually.

Uncommon (may affect up to 1 in 100 people):

• feeling elated or emotionally ‘high’ (mania)

Rare (may affect up to 1 in 1,000 people):

• yellow colouring of eyes or skin; this may suggest disturbance in liver function (jaundice)

Not known (frequency cannot be estimated from the available data):

• signs of infection such as sudden unexplainable high fever, sore throat and mouth ulcers (agranulocytosis). In rare cases mirtazapine can cause disturbances in the production of blood cells (bone marrow depression). Some people become less resistant to infection because mirtazapine can cause a temporary shortage of white blood cells (granulocytopenia). In rare cases mirtazapine can also cause a shortage of red and white blood cells, as well as blood platelets (aplastic anemia), a shortage of blood platelets (thrombocytopenia) or an increase in the number of white blood cells (eosinophilia).
• epileptic attack (convulsions)
• a combination of symptoms such as inexplicable fever, sweating, increased heart rate, diarrhoea, (uncontrollable) muscle contractions, shivering, overactive reflexes, restlessness, mood changes, unconsciousness and increased salivation. In very rare cases these can be signs of serotonin syndrome.
• thoughts of harming or killing yourself
• Reddish patches on the trunk which are target-like macules or circular, often with central blisters, skin peeling, ulcers of mouth, throat, nose, genitals and eyes. These serious skin rashes can be preceded by fever and flu-like symptoms (Stevens-Johnson syndrome, toxic epidermal necrolysis).
• Widespread rash, high body temperature and enlarged lymph nodes (DRESS syndrome or drug hypersensitivity syndrome).

Very common (may affect more than 1 in 10 people):

• increase in appetite and weight gain
• drowsiness or sleepiness
• headache
• dry mouth

Common (may affect up to 1 in 10 people):

• constipation
• lethargy
• dizziness
• shakiness or tremor
• nausea
• diarrhoea
• vomiting
• rash or skin eruptions (exanthema)
• pain in your joints (arthralgia) or muscles (myalgia)
• back pain
• feeling dizzy or faint when you stand up suddenly (orthostatic hypotension)
• swelling (typically in ankles or feet) caused by fluid retention (oedema)
• tiredness
• vivid dreams
• confusion
• feeling anxious
• sleeping problems
• Memory problems, which in most cases resolved when treatment was stopped.

Uncommon (may affect up to 1 in 100 people):

• abnormal sensation in the skin e.g. burning, stinging, tickling or tingling (paraesthesia)
• restless legs
• fainting (syncope)
• sensations of numbness in the mouth (oral hypoaesthesia)
• low blood pressure
• nightmares
• feeling agitated
• hallucinations
• urge to move

Rare (may affect up to 1 in 1,000 people):

• muscle twitching or contractions (myoclonus)
• aggression
• abdominal pain and nausea; this may suggest inflammation of the pancreas (pancreatitis)

Not known (frequency cannot be estimated from the available data):

• abnormal sensations in the mouth (oral paraesthesia)
• swelling in the mouth (mouth oedema), increase in saliva secretion or watery mouth
• swelling throughout the body (generalized oedema)
• localized swelling
• hyponatraemia
• inappropriate anti-diuretic hormone secretion
• speech disorder
• sleepwalking (somnambulism)
• blisters of the skin (dermatitis bullous)
• Skin rash, which may blister, and looks like small targets (central dark spots surrounded by a paler area, with a dark ring around the edge) called erythema multiforme
• Increased creatine kinase blood levels
• difficulty in passing urine (urinary retention)
• muscle pain, stiffness and/or weakness, darkening or discolouration of the urine (rhabdomyolysis)
• increased prolactin hormone levels in blood (hyperprolactinemia, including symptoms of enlarged breasts and/or milky nipple discharge)

In children under 18 years the following adverse events were observed commonly in clinical trials: significant weight gain, hives and increased blood triglycerides.

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard. By reporting side effects you can help provide more information on the safety of this medicine.

• The active substance is Mirtazapine. Each film coated tablet contains 15, 30 or 45 mg Mirtazapine.
• The other ingredients are lactose monohydrate, maize starch, hydroxypropyl cellulose, low substituted hydroxypropyl cellulose, magnesium stearate (E470b), silica colloidal anhydrous, hypromellose (E464) and titanium dioxide (E 171).
  The 15 mg tablets also contain yellow iron oxide (E 172).
  The 30 mg tablets also contain yellow iron oxide (E172), red iron oxide (E172) and black iron oxide (E172).

Mirtazapine 15 mg tablets are yellow, biconvex capsule shaped film coated tablets debossed with a score line in between “1” and “5” on one side and “MI” debossed on the other side.

Mirtazapine 30 mg tablets are reddish Brown biconvex capsule shaped film coated tablets debossed with a score line in between “3” and “0” on one side and “MI” debossed on the other side.

Mirtazapine 45 mg tablets are white, biconvex capsule shaped film coated tablets with “45” debossed on one side and “MI” debossed on the other side.

Mirtazapine 15, 30 and 45 mg tablets are available in PVC coated PVdC blister packs of 10/14/28/30/40/50/56/60/70/84/90/100/200/250/500 tablets. Not all packs may be marketed.

Marketing Authorisation Holder

Manufacturer

or